循环肿瘤细胞在胰腺癌诊疗中的应用

doi:10.3969/j.issn.1009-976X.2021.02.003

摘要/Abstract

中图分类号:

R735.9

程浩, 仇毓东. 循环肿瘤细胞在胰腺癌诊疗中的应用[J]. 岭南现代临床外科, 2021, 21(02): 141-145.

CHENG Hao, QIU Yu⁃dong. Application of circulating tumor cells in diagnosis and treatment of pancreatic cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 141-145.

[1] Sung H, Ferlay J, Siegel R, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021. doi: 10.3322/caac.21660.
[Online ahead of print].
[2] Khomiak A, Brunner M, Kordes M, et al.Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer[J]. Cancers, 2020, 12(11): 3234.
[3] Siegel R, Miller K, Fuchs H, Jemal A. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[4] Egawa S, Toma H, Ohigashi H, et al.Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society[J]. Pancreas, 2012, 41(7): 985-992.
[5] Ikemoto J, Serikawa M, Hanada K, et al.Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study[J]. Diagnostics, 2021, 11(2): 287.
[6] DiPardo B, Winograd P, Court C, Tomlinson J. Pancreatic cancer circulatingtumor cells: applications for personalized oncology[J]. Expert Rev Mol Diagn, 2018, 18(9): 809-820.
[7] Allen P, Kuk D, Castillo C, et al.Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma[J]. Ann Surg, 2017, 265(1): 185-191.
[8] Pokataev I, Fedyanin M, Polyanskaya E, et al.Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies[J]. ESMO Open, 2020, 5(1): e000578.
[9] Seaton M, Hanna A, Boutros C, Hanna N.Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database[J]. Ther Adv Med Oncol, 2019, 11:1758835919842438.
[10] Deng A, Wang C, Cohen S, et al.Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis[J]. Eur J Cancer, 2021, 147:17-28.
[11] Lee J, Park S, Lee Y, et al.Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA[J]. Mol Oncol, 2019, 13(8): 1623-1650.
[12] Martini V, Timme-Bronsert S, Fichtner-Feigl S, et al.Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives[J]. Cancers, 2019, 11(11): 1659.
[13] Sagami R, Yamao K, Nakahodo J, et al.Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma[J]. Cancers, 2021, 13(5): 945.
[14] Okano K, Suzuki Y.Strategies for early detection of resectable pancreatic cancer[J]. World J Gastroenterol, 2014, 20(32): 11230-11240.
[15] Mellby L, Nyberg A, Johansen J, et al.Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer[J]. J Clin Onco, 2018, 36(28): 2887-2894.
[16] Kim J, Bamlet W, Oberg A, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers [J]. Sci Transl Med, 2017, 9(398): eaah5583.
[17] Rhim A, Mirek E, Aiello N, et al.EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148:349-361.
[18] Rhim A, Thege F, Santana S, et al.Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions[J]. Gastroenterology, 2014, 146(3): 647-651.
[19] Liu H, Sun B, Wang S, et al.Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma[J]. Cell Physiol Biochem, 2017, 42(1): 373-382.
[20] Ankeny J, Court C, Hou S, et al.Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer[J]. Br J Cancer, 2016, 114(12): 1367-1375.
[21] Sefrioui D, Blanchard F, Toure E, et al.Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours[J]. Br J Cancer, 2017, 117(7): 1017-1025.
[22] Wei T, Zhang X, Zhang Q, et al.Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer[J]. Cancer Lett, 2019, 452:237-243.
[23] Cheng H, He W, Yang J, et al.Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer[J]. Cell Prolif, 2020, 53(9): e12880.
[24] Meng S, Tripathy D, Frenkel E, et al.Circulating tumor cells in patients with breast cancer dormancy[J]. Clin Cancer Res, 2004, 10(24): 8152-8162.
[25] Torphy R, Tignanelli C, Kamande J, et al.Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma[J]. PloS One, 2014, 9(2): e89474.
[26] Yu K, Ricigliano M, McCarthy B, et al. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma[J]. Cancers, 2018, 10(12): 467.
[27] Ren C, Han C, Zhang J, et al.Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy[J]. Cancer Biol Ther, 2011, 12(8): 700-706.
[28] Riva F, Dronov O, Khomenko D, et al.Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer[J]. Mol Oncol, 2016, 10(3): 481-493.
[29] Tjensvoll K, Nordgård O, Smaaland R.Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications[J]. Int J Cancer, 2014, 134(1): 1-8.
[30] Court C, Ankeny J, Sho S, et al.Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer[J]. Ann Surg Oncol, 2018, 25(4): 1000-1008.
[31] Song B, Kwon W, Kim H, et al.Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker[J]. Front Oncol, 2020, 10:616440.
[32] Wang Y, Yu X, Hartmann D, Zhou J.Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis[J]. HPB, 2020, 22(5): 660-669.
[33] Umer M, Vaidyanathan R, Nguyen N, Shiddiky M.Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies[J]. Biotechnol Adv, 2018, 36(4): 1367-1389.
[34] Chang M, Chang Y, Chen J, et al.Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Chem, 2016, 62(3): 505-513.
[35] Wu G, Zhu R, Li Y, et al.Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma[J]. Oncol Lett, 2018, 15(5): 7376-7382.
[36] Micalizzi D, Haber D, Maheswaran S.Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells[J]. Mol Oncol, 2017, 11(7): 770-780.
[37] Lowes L, Allan A.Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition[J]. Adv Clin Chem, 2018, 83:121-181.
[38] Gemenetzis G, Groot V, Yu J, et al.Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study[J]. Ann Surg, 2018, 268(3): 408-420.
[39] Poruk K, Valero V, Saunders, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma[J]. Ann Surg, 2016, 264(6): 1073-1081.
[40] Amantini C, Morelli M, Nabissi M, et al.Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival[J]. Front Oncol, 2019, 9:874.
[41] Sergeant G, van Eijsden R, Roskams T, et al. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery[J]. BMC Cancer, 2012, 12:527.
[42] Poruk K, Blackford A, Weiss M, et al.Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2017, 23(11): 2681-2690.
[43] Hussain S.Pancreatic Cancer: Current Progress and Future Challenges[J]. Int J Biol Sci, 2016, 12(3): 270-272.
[44] Tien Y, Kuo H, Ho B, et al.A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases[J]. Medicine, 2016, 95(16): e3407.
[45] White M, Lee A, Vicente D, et al.Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma[J]. Ann Surg Oncol, 2021. doi: 10.1245/s10434-020-09518-y.[Online ahead of print]
[46] Tao L, Su L, Yuan C, et al.Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer[J]. Cancer Manag Res, 2019, 11:7405-7425.
[47] Catenacci D, Chapman C, Xu P, et al. Acquisition of Portal Venous Circulating Tumor Cells FromPatients With Pancreaticobiliary Cancers by EndoscopicUltrasound [J]. Gastroenterology, 2015, 149(7): 1794-1803. e4.
[48] Chapman C, Ayoub F, Swei E, et al.Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers[J]. Pancreatology, 2020, 20(8): 1747-1754.
[49] Arnoletti J, Zhu X, Almodovar A, et al.Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation[J]. Pancreas, 2017, 46(1): 116-123.
[50] Arnoletti J, Fanaian N, Reza J, et al.Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation[J]. Cancer Biolo Ther, 2018, 19(10): 887-897.

循环肿瘤细胞在胰腺癌诊疗中的应用

Application of circulating tumor cells in diagnosis and treatment of pancreatic cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	龙吟, 宋兴东, 张磊. 中晚期肝癌转化治疗中的几个焦点问题[J]. 岭南现代临床外科, 2022, 22(02): 115-119.
[2]	邓静, 陈焕伟. 腹腔镜与开腹胰十二指肠切除术的安全性和疗效对比研究[J]. 岭南现代临床外科, 2022, 22(02): 120-125.
[3]	何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(01): 14-23.
[4]	林杏仪, 田振烽, 潘乐乐, 苏铭昕, 陈茵婷. 基于GEO数据库的胰腺癌循环肿瘤细胞代谢通路及关键基因研究[J]. 岭南现代临床外科, 2022, 22(01): 34-41.
[5]	楼文晖. 重视胰腺癌诊治的全流程管理[J]. 岭南现代临床外科, 2021, 21(01): 1-5.
[6]	韩世纪, 练国达, 陈少杰, 黄开红, 李佳佳. 人永生化胰腺星形细胞系的构建及其功能的验证[J]. 岭南现代临床外科, 2021, 21(01): 36-43.
[7]	袁贯平, 江志敏, 马冬, 潘梓春, 丁颖, 谢德荣. FOLFIRINOX方案与AG方案一线治疗晚期胰腺癌多中心观察性研究[J]. 岭南现代临床外科, 2021, 21(01): 53-58.
[8]	黄娴娴, 李苑华, 黄凤婷, 张世能, 庄燕妍. 利用CRISPR/Cas9技术敲除XPO1基因对胰腺癌细胞株生物学功能的影响[J]. 岭南现代临床外科, 2020, 20(03): 280-284.
[9]	彭宁福, 钟鉴宏, 朱少亮, 廖迎阳, 黎乐群. 胆管癌、胰腺癌及其癌前病变共同特征的研究现状[J]. 岭南现代临床外科, 2020, 20(02): 261-266.
[10]	李宣娜, 陈尚祥, 练国达, 陈少杰, 黄开红. 240例胰腺癌肝转移临床特征及预后分析[J]. 岭南现代临床外科, 2020, 20(02): 151-154.
[11]	李梓涛1，缪辉来2*. 超声内镜对胰腺囊性肿瘤的诊断与治疗的应用进展[J]. 岭南现代临床外科, 2019, 19(01): 106-109.
[12]	任潇凡1，李志花1*. 外泌体lncRNA CCAT1在胰腺癌中的表达及其临床意义[J]. 岭南现代临床外科, 2019, 19(01): 23-27.
[13]	张光涛1，梁悦2，李明华3. 质粒介导LAPTM4B过表达胰腺癌细胞株PANC?1的构建及鉴定[J]. 岭南现代临床外科, 2019, 19(01): 44-47.
[14]	韦禄胜，陆苑婷，叶会霖，周泉波，陈汝福. SATB-1与α-SMA在胰腺癌中的表达及其临床意义[J]. 岭南现代临床外科, 2018, 18(02): 195-200.
[15]	伍刚李莉 . 胰岛素瘤5例诊治体会[J]. 岭南现代临床外科, 2017, 17(06): 699-700.